The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)-A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD).
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
revised:
07
04
2024
received:
19
03
2024
accepted:
28
06
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
13
7
2024
Statut:
aheadofprint
Résumé
We conducted a clinical trial to determine the efficacy of the combination of vitamin E and/or docosahexaenoic acid (DHA) versus placebo in reducing liver fat content after 6 months of intervention in adults with MASLD. Adults with MASLD were randomised to one of four treatment arms (vitamin E 1000 mg/daily + DHA 1.89 g/daily or combination arm, vitamin E 1000 mg alone, DHA 1.89 g alone or placebo) following a 2:1:1:2 randomisation. The primary objective was to determine the efficacy of DHA + vitamin E versus placebo in reducing hepatic fat fraction (%) relative to baseline after 6 months of intervention. Secondary objectives were to determine the effect of vitamin E or DHA alone versus placebo on reducing liver fat at 6 months. Our cohort consisted of 203 subjects with a mean age of 51 years, 53% female, 91% White, 59% Hispanic ethnicity. The combination of vitamin E + DHA had no effect on the primary endpoint of reducing hepatic steatosis as determined by MRI-PDFF (p = 0.98). Neither vitamin E alone (p = 0.91) nor DHA alone (p = 0.14) significantly reduced hepatic steatosis compared to placebo. However, the trial was not powered adequately for this analysis. Compared with placebo, no statistically significant differences were detected in the 3-month or 6-month levels for ALT (U/L) or AST (U/L) in all three intervention groups. The combination of DHA + vitamin E or either agent alone did not demonstrate efficacy on reducing liver fat or aminotransferases in the studied population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : dsm-firmenich
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. https://doi.org/10.1002/hep.29367
Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59(2):150–156. https://doi.org/10.1111/apt.17846
Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, et al. Prospective evaluation of the prevalence of non‐alcoholic fatty liver disease and steatohepatitis in a large middle‐aged US cohort. J Hepatol. 2021;75(2):284–291. https://doi.org/10.1016/j.jhep.2021.02.034
Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta‐analysis. J Hepatol. 2019;71:793–801.
Schneider CV, Schneider KM, Raptis A, Huang H, Trautwein C, Loomba R. Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population. Aliment Pharmacol Ther. 2024;59(10):1271–1281. https://doi.org/10.1111/apt.17958
Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649–1659. https://doi.org/10.1038/s41395‐018‐0088‐6
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063–2072. https://doi.org/10.1056/NEJMra1503519
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497–509. https://doi.org/10.1056/NEJMoa2309000
Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double‐blind, placebo‐controlled phase 3 trial. Nat Med. 2023;29(11):2919–2928. https://doi.org/10.1038/s41591‐023‐02603‐1
Azzi A. Many tocopherols, one vitamin E. Mol Asp Med. 2018;61:92–103. https://doi.org/10.1016/j.mam.2017.06.004
Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol. 2009;3(4):445–451. https://doi.org/10.1586/egh.09.32
Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42(8):1481–1488. https://doi.org/10.2337/dc19‐0167
Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38(2):134–143. https://doi.org/10.1111/apt.12352
Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, et al. Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021;54(7):880–889. https://doi.org/10.1111/apt.16583
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685.
Hidayat K, Yang J, Zhang Z, Chen GC, Qin LQ, Eggersdorfer M, et al. Effect of omega‐3 long‐chain polyunsaturated fatty acid supplementation on heart rate: a meta‐analysis of randomized controlled trials. Eur J Clin Nutr. 2017;72:805–817. https://doi.org/10.1038/s41430‐017‐0052‐3
Ryan AS, Bailey‐Hall E, Nelson EB, Salem N Jr. The hypolipidemic effect of an ethyl ester of algal‐docosahexaenoic acid in rats fed a high‐fructose diet. Lipids. 2009;44(9):817–826. https://doi.org/10.1007/s11745‐009‐3330‐6
Maki KC, Palacios OM, Bell M, Toth PP. Use of supplemental long‐chain omega‐3 fatty acids and risk for cardiac death: an updated meta‐analysis and review of research gaps. J Clin Lipidol. 2017;11(5):1152–1160 e2. https://doi.org/10.1016/j.jacl.2017.07.010
Mori TA. Marine OMEGA‐3 fatty acids in the prevention of cardiovascular disease. Fitoterapia. 2017;123:51–58. https://doi.org/10.1016/j.fitote.2017.09.015
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population‐based cohort study. Gastroenterology. 2005;129(1):113–121. https://doi.org/10.1053/j.gastro.2005.04.014
Nobili V, Alisi A, Della Corte C, Risé P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013;23(11):1066–1070. https://doi.org/10.1016/j.numecd.2012.10.010
Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60(4):1211–1221. https://doi.org/10.1002/hep.27289
Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M, Group E‐AS. No significant effects of ethyl‐eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147(2):377–384.e1. https://doi.org/10.1053/j.gastro.2014.04.046
Kuratko C. Food‐frequency questionnaire for assessing long‐chain omega‐3 fatty‐acid intake: Re: assessing long‐chain omega‐3 polyunsaturated fatty acids: a tailored food‐frequency questionnaire is better. Nutrition. 2013;29(5):807–808. https://doi.org/10.1016/j.nut.2012.10.013
Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 2012;56(3):922–932. https://doi.org/10.1002/hep.25731
Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta‐analysis of randomized controlled trials. Nutrition. 2015;31(7–8):923–930. https://doi.org/10.1016/j.nut.2014.11.018
Guo XF, Yang B, Tang J, Li D. Fatty acid and non‐alcoholic fatty liver disease: meta‐analyses of case‐control and randomized controlled trials. Clin Nutr. 2018;37(1):113–122. https://doi.org/10.1016/j.clnu.2017.01.003
He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, et al. Effectiveness of Omega‐3 polyunsaturated fatty acids in non‐alcoholic fatty liver disease: a meta‐analysis of randomized controlled trials. PLoS One. 2016;11(10):e0162368. https://doi.org/10.1371/journal.pone.0162368
Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega‐3 supplementation and non‐alcoholic fatty liver disease: a systematic review and meta‐analysis. J Hepatol. 2012;56(4):944–951. https://doi.org/10.1016/j.jhep.2011.08.018